Differential effects of calcium antagonists on ABCG2/BCRP-mediated drug resistance and transport in SN-38-resistant HeLa cells

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 603-609

  Takara, Kohji ^a   Matsubara, Mika ^b   Yamamoto, Kazuhiro ^b   Minegaki, Tetsuya ^b   Takegami, Shigehiko ^b   Takahashi, Minoru ^a   Yokoyama, Teruyoshi ^a   Okumura, Katsuhiko ^a  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

ABCG2 BCRP; Calcium antagonist; Drug resistance; HeLa; Transport

Indexed keywords

AMLODIPINE BESYLATE; BENIDIPINE; BREAST CANCER RESISTANCE PROTEIN; CALCIUM ANTAGONIST; DILTIAZEM; FELODIPINE; MITOXANTRONE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; HELA CELL; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; NEOPLASM PROTEINS;

EID: 84863406196     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.734     Document Type: Article

References (21)

1. Schrama D, Reisfeld RA and Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147-159, 2006.
2. Le Toumeau C, Faivre S and Raymond E: New developments in multitargeted therapy for patients with solid tumors. Cancer Treat Rev 34: 37-48, 2008. (Pubitemid 351168610)
3. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer. Curr Pharm Des 12: 273-286, 2006.
4. Mimeault M, Hauke R and Batra SK: Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83: 673-691, 2008. (Pubitemid 351559599)
5. Eckford PD and Sharom FJ: ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109: 2989-3011, 2009.
6. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981. (Pubitemid 11114605)
7. Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K, Sakoda R and Akiyama S: Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res 50: 3055-3061, 1990. (Pubitemid 20170762)
8. Jaffrézou JP, Herbert JM, Levade T, Gau MN, Chatelain P and Laurent G: Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. J Biol Chem 266: 19858-19864, 1991. (Pubitemid 21908305)
9. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T and Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 70: 1491-1500, 2002. (Pubitemid 34164543)
10. Viale M, Cordazzo C, de Totero D, Budriesi R, Rosano C, Leoni A, Ioan P, Aiello C, Croce M, Andreani A, Rambaldi M, Russo P, Chiarini A and Spinelli D: Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Invest New Drugs 29: 98-109, 2011.
11. 2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci 16: 159-165, 2002.
12. Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N and Yokoyama T: Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 278: 88-96, 2009.
13. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N and Yokoyama T: Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 58: 785-793, 2006. (Pubitemid 44351259)
14. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K and Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25: 771-778, 2002. (Pubitemid 40036714)
15. Takara K, Horibe S, Obata Y, Yoshikawa E, Ohnishi N and Yokoyama T: Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull 28: 138-142, 2005. (Pubitemid 40879798)
16. Takara K, Tsujimoto M, Ohnishi N and Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 292: 190-194, 2002. (Pubitemid 34687347)
17. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
18. Shukla S, Robey RW, Bates SE and Ambudkar SV: The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45: 8940-8951, 2006. (Pubitemid 44100690)
19. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD and Mao Q: BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22: 2023-2034, 2005. (Pubitemid 41821581)
20. Zhou XF, Yang X, Wang Q, Coburn RA and Morris ME: Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos 33: 1220-1228, 2005. (Pubitemid 41043766)
21. Katoh M, Nakajima M, Yamazaki H and Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 17: 1189-1197, 2000.